TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. (RNAZ) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · RNAZ · as of Jun 9, 2026
Activity summary
Buy transactions
7
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
∞
Buy/Sell (by trades)
Overall sentiment
TransCode Therapeutics, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
RNAZ insider buying and selling by quarter
RNAZ insider selling · RNAZ insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Recent insider transactions
RNAZ executive sell shares · RNAZ board member insider trading · RNAZ insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Sep 28, 2023 | Fitzgerald Thomas A CFO · Director | Purchase | 49,350 | $25K | Form 4 |
| Sep 28, 2023 | Dudley Robert Michael CEO · Director | Purchase | 98,000 | $50K | Form 4 |
| Jun 21, 2023 | Dudley Robert Michael CEO · Director | Purchase | 12,000 | $32K | Form 4 |
| Jun 20, 2023 | Dudley Robert Michael CEO · Director | Purchase | 6,607 | $17K | Form 4 |
| Jun 9, 2023 | Dudley Robert Michael CEO · Director | Purchase | 19,000 | $52K | Form 4 |
| Sep 14, 2022 | Dudley Robert Michael CEO · Director | Purchase | 20,000 | $23K | Form 4 |
| Jun 16, 2022 | Fitzgerald Thomas A CFO | Purchase | 12,000 | $15K | Form 4 |
| May 27, 2022 | Dudley Robert Michael CEO | Purchase | 28,000 | $52K | Form 4 |
Fitzgerald Thomas A
CFO · Director
Date
Sep 28
Shares
49,350
Price
$0.51
Value
$25K
Dudley Robert Michael
CEO · Director
Date
Sep 28
Shares
98,000
Price
$0.51
Value
$50K
Dudley Robert Michael
CEO · Director
Date
Jun 21
Shares
12,000
Price
$2.65
Value
$32K
Dudley Robert Michael
CEO · Director
Date
Jun 20
Shares
6,607
Price
$2.55
Value
$17K
Dudley Robert Michael
CEO · Director
Date
Jun 9
Shares
19,000
Price
$2.76
Value
$52K
Dudley Robert Michael
CEO · Director
Date
Sep 14
Shares
20,000
Price
$1.15
Value
$23K
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About RNAZ insider trading
RNAZ insider trades
TransCode Therapeutics, Inc. (RNAZ) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including RNAZ. Over the past 12 months, 0 insiders have filed transactions with the SEC. RNAZ insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For TransCode Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
RNAZ insider trading · 5 questionsThe insiders of TransCode Therapeutics, Inc. (RNAZ) include executives and directors such as RNAZ, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026